» Articles » PMID: 9451319

The Acute Asthmatic Patient in the ED: to Admit or Discharge

Overview
Journal Am J Emerg Med
Specialty Emergency Medicine
Date 1998 Feb 6
PMID 9451319
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Treating asthma in the emergency department (ED) always involves the potentially difficult decision as to whether to discharge the patient, to continue treatment, or to admit to the hospital. The following are useful guidelines. (1) The duration of the bronchospasm, frequency of visits, history of previous endotracheal intubation, pulse rate, and accessory muscle use are findings affecting successful discharge from the ED. (2) Patients with peak expiratory flow rate (PEFR) of < 20% and who do not respond to inhalant therapy, with PEFR values persisting at < 40% of predicted, will require 4 or more days to resolve and should be admitted to the hospital. (3) Patients with a PEFR between 40% and 70% of predicted after initial inhalant therapy may well be responsive to steroids in the ED, but an ED will adequately need to care for the patient for 5 to 12 hours while waiting for the onset of action of glucocorticoids. Discharged with glucocorticoids, this group has a 6% relapse rate within 10 days of the ED visit. (4) Patients with a PEFR of > or = 70% have a 14% relapse rate after discharge without glucocorticoids. Other reasons to consider admission are pneumonia, barotrauma, lability, prominent psychiatric difficulties, poor access to medications, poor educability, fear of steroids, patients on glucocorticoids or those who have recently stopped glucocorticoids, and evening discharges of patients from the ED, which all predispose to relapses of acute asthma. To decrease the relapse rate, provocative factors should be reviewed with the patient, as well as access to medication and use of spacers, inhaler techniques, PEFR meters, self-management plans, and referral to a defined appointment at 24 to 48 hours of the ED visit.

Citing Articles

GEMA 5.3. Spanish Guideline on the Management of Asthma.

Plaza Moral V, Alobid I, Alvarez Rodriguez C, Blanco Aparicio M, Ferreira J, Garcia G Open Respir Arch. 2023; 5(4):100277.

PMID: 37886027 PMC: 10598226. DOI: 10.1016/j.opresp.2023.100277.


The patient with dyspnea. Rational diagnostic evaluation.

Brenner S, Guder G Herz. 2014; 39(1):8-14.

PMID: 24509867 DOI: 10.1007/s00059-014-4057-6.


Molecular characterization of Arabidopsis PHO80-like proteins, a novel class of CDKA;1-interacting cyclins.

Torres Acosta J, de Almeida Engler J, Raes J, Magyar Z, De Groodt R, Inze D Cell Mol Life Sci. 2004; 61(12):1485-97.

PMID: 15197472 PMC: 11138636. DOI: 10.1007/s00018-004-4057-4.